Premium Grade | UK Supply | Research Peptide | COA Certified | >99% Purity | Worldwide Delivery

(Tetrasectide, 44 amino acids)

Brief Summary

CJC-1295+DAC is a modified peptide research compound studied in laboratory settings for its interaction with growth hormone releasing hormone pathways and extended activity profile analysis. It is commonly examined in controlled investigational models focused on receptor signalling, endocrine response patterns, and comparative peptide mechanism research. Within scientific supply catalogues, CJC-1295+DAC is valued for in vitro and preclinical studies involving pathway duration, secretion related marker observation, and structured peptide design investigation. Its role in research centres on analytical evaluation, documented laboratory handling, and consistent experimental planning, making it suitable for professional scientific environments requiring clear, research focused peptide supply standards.

Product Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic peptide analogue of growth hormone–releasing hormone (GHRH), developed to provide prolonged stimulation of endogenous growth hormone secretion. Through the incorporation of a Drug Affinity Complex, CJC-1295 is engineered to reversibly bind to circulating plasma proteins, significantly extending its functional activity compared to native GHRH and shorter-acting analogues. Within research environments, CJC-1295 with DAC is utilised to examine sustained growth hormone signalling, endocrine rhythm modulation, and long-term activation of the GH–IGF-1 axis. Its extended activity profile allows researchers to study continuous hormonal stimulation while maintaining physiological regulation mechanisms, making it a valuable compound for investigations requiring stable and prolonged endocrine engagement.

Scientific Background

CJC-1295 is structurally based on growth hormone–releasing hormone, with targeted amino acid substitutions that enhance resistance to enzymatic degradation. The addition of the Drug Affinity Complex enables covalent but reversible binding to serum albumin, dramatically extending the peptide's half-life and allowing sustained interaction with GHRH receptors located on somatotroph cells of the anterior pituitary. Upon receptor activation, CJC-1295 with DAC initiates intracellular signalling pathways involving cyclic AMP (cAMP) and protein kinase A, leading to increased synthesis and pulsatile release of growth hormone. This prolonged stimulation results in elevated and sustained downstream production of insulin-like growth factor-1 (IGF-1), a key mediator of cellular growth, metabolic regulation, and tissue maintenance.

Research Applications

CJC-1295 with DAC is extensively researched in endocrinology and metabolic science, particularly in studies examining prolonged growth hormone exposure and its systemic effects. Researchers utilise this peptide to investigate sustained GH–IGF-1 signalling, endocrine rhythm stability, and the physiological impact of extended hormone release patterns. In metabolic research, CJC-1295 with DAC is explored for its role in lipid metabolism regulation, energy utilisation pathways, and nutrient partitioning. Additionally, CJC-1295 with DAC is used in studies focused on cellular regeneration, protein synthesis, and tissue maintenance processes associated with growth hormone signalling.

Technical Specifications

• Contents: 5mg CJC-1295 + DAC
• Form: Lyophilized powder
• Purity: >99% (HPLC Verified)
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• Peptide Length: 44 Amino-Acids
• pH Range: 4.5-7.0
• Storage: Store between 1°C and 3°C